德国两例接受利妥昔单抗治疗患者的严重蜱传脑炎病例：对诊断和预防的启示
Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention.
作者信息
Steininger Philipp A, Bobinger Tobias, Dietrich Wenke, Lee De-Hyung, Knott Michael, Bogdan Christian, Korn Klaus, Lang Roland
机构信息
Institute of Clinical and Molecular Virology, University Hospital of Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Department of Neurology, University Hospital of Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
出版信息
Open Forum Infect Dis. 2017 Sep 26;4(4):ofx204. doi: 10.1093/ofid/ofx204. eCollection 2017 Fall.
Rituximab (RTX) has become a standard therapy for certain B cell malignancies and autoimmune diseases. We report 2 RTX-treated patients who developed severe tick-borne encephalitis virus (TBEV) infection. The inability to generate new antibody responses renders RTX-treated patients susceptible to TBEV, impedes laboratory diagnosis, and necessitates preventive vaccination in endemic areas.
利妥昔单抗（RTX）已成为某些B细胞恶性肿瘤和自身免疫性疾病的标准疗法。我们报告了2例接受RTX治疗后发生严重蜱传脑炎病毒（TBEV）感染的患者。无法产生新的抗体反应使接受RTX治疗的患者易感染TBEV，阻碍实验室诊断，并需要在流行地区进行预防性疫苗接种。
Zotero 插件